Literature DB >> 25797752

Postmastectomy radiation for N2/N3 breast cancer: factors associated with low compliance rate.

Quyen D Chu1, Gloria Caldito2, J Karen Miller3, Beth Townsend3.   

Abstract

BACKGROUND: The National Comprehensive Cancer Network and American Society of Clinical Oncology guidelines recommend postmastectomy radiation therapy (PMRT) for women with N2/N3 breast cancer. We examined the compliance rate of PMRT using the National Cancer Data Base and determined what factors are associated with low compliance rate with PMRT. STUDY
DESIGN: The National Cancer Data Base, comprising 2,720,368 breast cancer cases diagnosed between 1998 and 2011, was evaluated. From this database, 56,990 women with N2/N3 diseases were evaluated. Statistics used include chi-square test, 2-sample t-test or Wilcoxon rank-sum test, and multivariate analysis.
RESULTS: Mean age of the patients was 58 years and median follow-up was 61 months. The majority of patients were from a comprehensive community cancer programs (59%), were Caucasian (81%), had health insurance (96%), resided in urban communities (98%), and had no comorbidities (83%). Approximately 82% received chemotherapy, but only 65% had PMRT. Factors associated with PMRT are tumor grade (p = 0.03), regional lymph node surgery (p = 0.03), readmission within 30 days of surgical discharge (p = 0.03), receipt of chemotherapy (p < 0.01) and hormonal therapy (p < 0.01), and 30-day mortality (p < 0.01). Socioeconomic variables, such as facility type (p = 0.85), facility geographic location (p = 0.27), race/ethnicity (p = 0.12), insurance status (p = 0.10), income level (p = 0.43), education level (p = 0.86), residential location (p = 0.83), and comorbidities (p = 0.83) were not contributory factors. Independent variables predicting compliance with PMRT include receipt of chemotherapy (odds ratio = 4.55; p < 0.01), readmission within 30 days after surgery (odds ratio = 1.14; p = 0.01), and alive within 30 days after surgery (odds ratio = 1.55; p = 0.04).
CONCLUSIONS: One third of patients with N2/N3 disease did not receive PMRT. Socioeconomic variables were not contributory factors. Noncompliance with PMRT is related to lack of receipt of chemotherapy, nonreadmission, or death within 30 days after surgery.
Copyright © 2015 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25797752     DOI: 10.1016/j.jamcollsurg.2014.12.045

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  5 in total

1.  The Predictive Effect of the 8th AJCC Pathological Prognostic Staging on the Benefit of Postmastectomy Radiotherapy in N2/N3 Breast Cancer.

Authors:  Shi-Ping Yang; Ping Zhou; Chen-Lu Lian; Zhen-Yu He; San-Gang Wu
Journal:  Breast Cancer (Dove Med Press)       Date:  2022-05-13

Review 2.  Hypofractionated radiation treatment in the management of breast cancer.

Authors:  Apar Gupta; Nisha Ohri; Bruce G Haffty
Journal:  Expert Rev Anticancer Ther       Date:  2018-06-26       Impact factor: 4.512

3.  Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast Cancer.

Authors:  Catherine Loveland-Jones; Heather Lin; Yu Shen; Isabelle Bedrosian; Simona Shaitelman; Henry Kuerer; Wendy Woodward; Naoto Ueno; Vicente Valero; Gildy Babiera
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-10       Impact factor: 7.038

4.  The incidence of postoperative radiotherapy-induced acute dermatitis in breast cancer and its influencing factors for Chinese women.

Authors:  Jingxian Ding; Yonghong Guo; Qingge Li; Jun Chen; Pinghua Hu; Qiuming Liu; Yali Cao; Jiong Wu
Journal:  Onco Targets Ther       Date:  2018-03-23       Impact factor: 4.147

5.  Radiotherapy after mastectomy has significant survival benefits for inflammatory breast cancer: a SEER population-based retrospective study.

Authors:  Zhi-Wen Li; Miao Zhang; Yong-Jing Yang; Zi-Jun Zhou; Yan-Ling Liu; Hang Li; Bo Bao; Jian-Dong Diao; Dun-Wei Wang
Journal:  PeerJ       Date:  2020-02-03       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.